Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 20:39 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
OtherCommon Stock | 600,191 | $1.33 | $799,994.58 |
DisclosureSEC source: 0001193125-26-340392 · ownership.xml · nonDerivative · entry 2 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By David Portnoy Irrevocable 2026 Trust Agreement Disclosed balance after: 600,191 F1 · kind: On August 5, 2026, the Reporting Person transferred 600,191 shares of the Issuer's common stock to the David Portnoy Irrevocable 2026 Trust Agreement (the "Trust"). In connection with the transfer, the Trust borrowed $800,000.26, the proceeds of which were used to satisfy outstanding indebtedness of the Reporting Person. The Reporting Person personally guaranteed the Trust's repayment obligations. The price reported in Column 4 represents $800,000.26 divided by the 600,191 shares transferred and does not represent the fair market value of the shares. Deborah Portnoy, the Reporting Person's spouse, is the sole trustee. The Reporting Person is not a beneficiary of the Trust, has no power to revoke the Trust and, for purposes of Section 16 reporting, disclaims beneficial ownership of the shares held by the Trust except to the extent of any pecuniary interest therein. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:39 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
OtherCommon Stock | 600,191 | $1.33 | $799,994.58 |
DisclosureSEC source: 0001193125-26-340392 · ownership.xml · nonDerivative · entry 1 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,438 F1 · kind: On August 5, 2026, the Reporting Person transferred 600,191 shares of the Issuer's common stock to the David Portnoy Irrevocable 2026 Trust Agreement (the "Trust"). In connection with the transfer, the Trust borrowed $800,000.26, the proceeds of which were used to satisfy outstanding indebtedness of the Reporting Person. The Reporting Person personally guaranteed the Trust's repayment obligations. The price reported in Column 4 represents $800,000.26 divided by the 600,191 shares transferred and does not represent the fair market value of the shares. Deborah Portnoy, the Reporting Person's spouse, is the sole trustee. The Reporting Person is not a beneficiary of the Trust, has no power to revoke the Trust and, for purposes of Section 16 reporting, disclaims beneficial ownership of the shares held by the Trust except to the extent of any pecuniary interest therein. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:30 UTC |
TAYMANS JILL MVP Finance, CFO
|
Exercise / conversionStock Option · Derivative | 7,500 | $3.10 Strike: $3.10 | $23,250.00 |
DisclosureSEC source: 0001193125-26-248432 · ownership.xml · derivative · entry 8 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2026-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:30 UTC |
TAYMANS JILL MVP Finance, CFO
|
Exercise / conversionCommon Stock | 7,500 | $3.10 | $23,250.00 |
DisclosureSEC source: 0001193125-26-248432 · ownership.xml · nonDerivative · entry 1 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantStock Option · Derivative | 150,000 | $3.89 Strike: $3.89 | $583,500.00 |
DisclosureSEC source: 0001193125-26-009073 · ownership.xml · derivative · entry 19 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-07 F9 · derivative.exercise_date: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantStock Option · Derivative | 50,000 | $3.89 Strike: $3.89 | $194,500.00 |
DisclosureSEC source: 0001193125-26-009073 · ownership.xml · derivative · entry 18 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-01-07 F8 · derivative.exercise_date: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC |
Mikulinsky OlegChief Information Officer
|
GrantStock Option · Derivative | 20,000 | $3.54 Strike: $3.54 | $70,800.00 |
DisclosureSEC source: 0001193125-26-009069 · ownership.xml · derivative · entry 10 Mikulinsky Oleg · CIK 0001544572 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-07 F6 · derivative.exercise_date: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC |
Mikulinsky OlegChief Information Officer
|
GrantStock Option · Derivative | 10,000 | $3.54 Strike: $3.54 | $35,400.00 |
DisclosureSEC source: 0001193125-26-009069 · ownership.xml · derivative · entry 9 Mikulinsky Oleg · CIK 0001544572 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-07 F5 · derivative.exercise_date: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC |
Portnoy Mark L.Director · Co-CEO · 10% owner
|
GrantStock Option · Derivative | 25,000 | $3.89 Strike: $3.89 | $97,250.00 |
DisclosureSEC source: 0001193125-26-009068 · ownership.xml · derivative · entry 12 Portnoy Mark L. · CIK 0001529249 · Director · Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-01-07 F7 · derivative.exercise_date: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC |
Portnoy Mark L.Director · Co-CEO · 10% owner
|
GrantStock Option · Derivative | 50,000 | $3.89 Strike: $3.89 | $194,500.00 |
DisclosureSEC source: 0001193125-26-009068 · ownership.xml · derivative · entry 11 Portnoy Mark L. · CIK 0001529249 · Director · Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-01-07 F6 · derivative.exercise_date: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC |
TAYMANS JILL MVP Finance, CFO
|
GrantStock Option · Derivative | 20,000 | $3.54 Strike: $3.54 | $70,800.00 |
DisclosureSEC source: 0001193125-26-009067 · ownership.xml · derivative · entry 8 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-07 F5 · derivative.exercise_date: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC |
TAYMANS JILL MVP Finance, CFO
|
GrantStock Option · Derivative | 10,000 | $3.54 Strike: $3.54 | $35,400.00 |
DisclosureSEC source: 0001193125-26-009067 · ownership.xml · derivative · entry 7 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-07 F4 · derivative.exercise_date: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:00 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 273 | $4.10 | $1,119.30 |
DisclosureSEC source: 0001193125-25-293823 · ownership.xml · nonDerivative · entry 5 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for son Disclosed balance after: 11,212 Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:00 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 406 | $4.09 | $1,660.54 |
DisclosureSEC source: 0001193125-25-293823 · ownership.xml · nonDerivative · entry 4 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for son Disclosed balance after: 11,804 Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:00 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 677 | $4.09 | $2,768.93 |
DisclosureSEC source: 0001193125-25-293823 · ownership.xml · nonDerivative · entry 3 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for son Disclosed balance after: 12,214 Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:00 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 800 | $4.04 | $3,232.00 |
DisclosureSEC source: 0001193125-25-293823 · ownership.xml · nonDerivative · entry 2 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 847,629 Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:00 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 289 | $4.00 | $1,156.00 |
DisclosureSEC source: 0001193125-25-293823 · ownership.xml · nonDerivative · entry 1 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 846,829 Read SEC document |
| November 19, 2025 Filed Nov 19, 2025 22:11 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 1,921 | $4.08 | $7,837.68 |
DisclosureSEC source: 0001193125-25-288306 · ownership.xml · nonDerivative · entry 3 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 846,540 F1 · price: The price reported is a weighted average price of $4.08. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 22:11 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 640 | $4.09 | $2,617.60 |
DisclosureSEC source: 0001193125-25-288306 · ownership.xml · nonDerivative · entry 2 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 844,619 Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 22:11 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 1,429 | $4.00 | $5,716.00 |
DisclosureSEC source: 0001193125-25-288306 · ownership.xml · nonDerivative · entry 1 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843,979 Read SEC document |
| November 12, 2025 Filed Nov 12, 2025 22:01 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 2,040 | $4.12 | $8,404.80 |
DisclosureSEC source: 0001193125-25-277890 · ownership.xml · nonDerivative · entry 3 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 842,550 F2 · price: The price reported is a weighted average price of $4.12. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 22:01 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 2,474 | $4.13 | $10,217.62 |
DisclosureSEC source: 0001193125-25-277890 · ownership.xml · nonDerivative · entry 2 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 840,510 F1 · price: The price reported is a weighted average price of $4.13. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 22:01 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 1,026 | $4.18 | $4,288.68 |
DisclosureSEC source: 0001193125-25-277890 · ownership.xml · nonDerivative · entry 1 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838,036 Read SEC document |
| November 04, 2025 Filed Nov 4, 2025 22:26 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 5,000 | $4.40 | $22,000.00 |
DisclosureSEC source: 0001193125-25-265046 · ownership.xml · nonDerivative · entry 2 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 837,010 F1 · price: The price reported is a weighted average price of $4.40. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 22:26 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
GrantCommon Stock | 4,666 | $4.45 | $20,763.70 |
DisclosureSEC source: 0001193125-25-265046 · ownership.xml · nonDerivative · entry 1 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 832,010 Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 21:00 UTC |
Mizrahi DanielDirector
|
GrantStock Option · Derivative | 5,300 | $4.35 Strike: $4.35 | $23,055.00 |
DisclosureSEC source: 0001193125-25-248885 · ownership.xml · derivative · entry 6 Mizrahi Daniel · CIK 0001888345 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2035-10-21 F1 · derivative.exercise_date: Stock options vest at a rate of 1/12 per month commencing on October 21, 2025. Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 21:00 UTC |
Berger Harold D.Director
|
GrantStock Option · Derivative | 5,300 | $4.35 Strike: $4.35 | $23,055.00 |
DisclosureSEC source: 0001193125-25-248884 · ownership.xml · derivative · entry 9 Berger Harold D. · CIK 0001529398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2035-10-21 Read SEC document |
| September 18, 2025 Filed Sep 18, 2025 20:53 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 1,751 | $4.49 | $7,861.99 |
DisclosureSEC source: 0001193125-25-207528 · ownership.xml · nonDerivative · entry 4 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Corporation Disclosed balance after: 161,833 F4 · ownership.nature: Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary. Read SEC document |
| September 18, 2025 Filed Sep 18, 2025 20:53 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 3,411 | $4.46 | $15,213.06 |
DisclosureSEC source: 0001193125-25-207528 · ownership.xml · nonDerivative · entry 3 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 827,344 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.45 to $4.50, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2025 Filed Sep 18, 2025 20:53 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 5,564 | $4.43 | $24,648.52 |
DisclosureSEC source: 0001193125-25-207528 · ownership.xml · nonDerivative · entry 2 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 823,933 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.41 to $4.45, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 20:53 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 6,449 | $4.46 | $28,762.54 |
DisclosureSEC source: 0001193125-25-207528 · ownership.xml · nonDerivative · entry 1 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 818,369 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.40 to $4.47, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 2,087 | $4.48 | $9,349.76 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 10 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Corporation Disclosed balance after: 57,306 F5 · ownership.nature: Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary. Read SEC document |
| September 10, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 7,200 | $4.48 | $32,256.00 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 9 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Corporation Disclosed balance after: 160,082 F4 · ownership.nature: Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary. Read SEC document |
| September 10, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 7,178 | $4.42 | $31,726.76 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 8 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 811,920 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.45, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 4,817 | $4.47 | $21,531.99 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 7 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 107,403 Read SEC document |
| September 10, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 11,035 | $4.40 | $48,554.00 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 6 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 268,878 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.45, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 156 | $4.49 | $700.44 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 5 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for son Disclosed balance after: 10,939 Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 156 | $4.48 | $698.88 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 4 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for son Disclosed balance after: 11,398 Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 185 | $4.49 | $830.65 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 3 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for son Disclosed balance after: 11,537 Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 4,815 | $4.49 | $21,619.35 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 2 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 257,843 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.48 to $4.49, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 21:22 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 5,271 | $4.31 | $22,718.01 |
DisclosureSEC source: 0000950170-25-114029 · ownership.xml · nonDerivative · entry 1 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 253,028 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.32, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 2, 2025 21:18 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
OtherCommon Stock | 15,611 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-112560 · ownership.xml · nonDerivative · entry 12 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for Daughter Disclosed balance after: 0 F4 · acquired: Child reached age of majority and reporting person no longer has beneficial ownership. Read SEC document |
| August 27, 2025 Filed Aug 27, 2025 21:23 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 6,218 | $4.44 | $27,607.92 |
DisclosureSEC source: 0000950170-25-111745 · ownership.xml · nonDerivative · entry 6 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 247,757 Read SEC document |
| August 27, 2025 Filed Aug 27, 2025 21:23 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 7,860 | $4.42 | $34,741.20 |
DisclosureSEC source: 0000950170-25-111745 · ownership.xml · nonDerivative · entry 4 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 401K Disclosed balance after: 164,182 F9 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.41 to $4.44, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 21:23 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 11,101 | $4.44 | $49,288.44 |
DisclosureSEC source: 0000950170-25-111745 · ownership.xml · nonDerivative · entry 3 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 401K Disclosed balance after: 156,322 F8 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.36 to $4.46, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:23 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 4,500 | $4.53 | $20,385.00 |
DisclosureSEC source: 0000950170-25-111745 · ownership.xml · nonDerivative · entry 5 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 241,539 F7 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.48 to $4.55, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:23 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 5,000 | $4.65 | $23,250.00 |
DisclosureSEC source: 0000950170-25-111745 · ownership.xml · nonDerivative · entry 2 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 401K Disclosed balance after: 145,221 Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:23 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 4,500 | $4.65 | $20,925.00 |
DisclosureSEC source: 0000950170-25-111745 · ownership.xml · nonDerivative · entry 1 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 401K Disclosed balance after: 140,221 Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 21:00 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 885 | $4.37 | $3,867.45 |
DisclosureSEC source: 0000950170-25-110173 · ownership.xml · nonDerivative · entry 4 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 401K Disclosed balance after: 135,721 Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:00 UTC |
PORTNOY DAVIDDirector · Chairman, Co-CEO · 10% owner
|
PurchaseCommon Stock | 9,327 | $4.37 | $40,758.99 |
DisclosureSEC source: 0000950170-25-110173 · ownership.xml · nonDerivative · entry 3 PORTNOY DAVID · CIK 0001315416 · Director · Chairman, Co-CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By 401K Disclosed balance after: 134,836 F9 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.23 to $4.50, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.